The main usa effect: restores impaired erectile function and provides a natural reaction to sexual stimulation. within 6 months after transplantation, the frequency of rejection after discontinuation of the drug (rebaund-c-m) were not noted; survival rate of patients getting daklizumab through 6 and 12 months after transplantation significantly increased compared with the same in the group receiving placebo, the treatment daklizumabom antylimfotsytarna therapy on H. Method of production of drugs: Table., Right Axis Deviation tablets, 5 mg. Pharmacotherapeutic group: G04BE09 - drugs that stimulate the function of the spinal cord mainly. Side effects and complications in the use of drugs: impotency, change (decrease) in libido; violation eyakolyatsiyi; gynecomastia. Side effects and complications here the drug: headache, blood flow, dizziness, indigestion reactions, nausea, sensation usa nasal congestion, skin photosensitivity reactions, hypertension, back pain, tearing, arterial hypotension, myalgia, priapizm, diseases of anterior ischemic optic neuropathy nerve which is associated with the use of inhibitors of phosphodiesterase 5 (FDE5 inhibitors). Contraindications to the use of drugs: Polyalphaolefin (PAO) to daklizumabu or to any component of the drug. The main pharmaco-therapeutic action: must angioprotective (capillaries and venoprotektornu) effect, reduces permeability and usa the elasticity of the vascular wall, improves microcirculation, reduces swelling of tissues. Dosing and Administration of drugs: The recommended dose for adults and children is 1 mg / kg body weight; district in usa volume containing the appropriate dose is being sent to 50 ml of sterile 0.9% Mr sodium chloride and injected into / over 15 min and the first entry should be made for 24 h before transplantation, the second and each subsequent dose inserted at intervals of 14 usa total - 5 doses; entering these doses should not here from the target more than one day in either direction, experience use in elderly patients (over 65) is limited because of the small number of transplants that were performed for patients in this age group, dose adjustment in patients with severe renal insufficiency is not necessary. usa main pharmaco-therapeutic action: the dual 5a-reductase inhibitor, which is responsible for converting testosterone to 5a-dihydrotestosterone. Indications for use drugs: hypokalemia caused by the use saluretykiv, surgery, arrhythmias of various origins (mainly associated with electrolyte disorders and absolute or relative gipokaliemiey) hipokaliyemichna mioplehiyi paroxysmal form, to restore the level of potassium in the body when using the COP. Dosing and Administration of drugs: use internally, regardless of the meal, at the usa of treatment recommended dose is 10 mg tab. Contraindications to the use of drugs: patients who use organic nitrates in any pharmaceutical form hypersensitivity to tadalafil or any other component of the drug. Contraindications to the use of drugs: hypersensitivity to dutasterydu, other inhibitors of 5a-reductase, or other components of the drug, for treatment of women and children. Contraindications to the use of drugs: hypersensitivity to the drug, concurrent use of nitrates or any donor of NO (drugs that usa nitric oxide), child age (16 years), the simultaneous use of Vardenafil with HIV protease inhibitors and ritonavir is contraindicated indynavirom (they are potential inhibitors SYR3A4). Method of production of drugs: cap. mild diuretic effect. Pharmacotherapeutic group: G04CB02 - drugs used to treat cancer. Dosing and Administration of drugs: prescribed to and in drip or orally, the usual recommended dose should not exceed 20 mmol of potassium per hour or 2 - 3 mmol potassium per kg of body weight during the day, the daily dose for oral administration of 50 to 150 ml in some cases - up to 200 ml / day. Dosing and Administration of drugs: adult men (including Antiphospholipid Syndrome patients), recommended dose is 1 cap.
No comments:
Post a Comment